Myelofibrosis (MF) Treatment Market

Myelofibrosis (MF) Treatment Market Snapshot (2023 to 2033)

The global myelofibrosis (MF) treatment market is expected to reach USD 749.05 Million in 2023 and is projected to exhibit a CAGR of 5.5% from 2023 to 2033. MF is becoming more prevalent around the globe and early diagnosis is driving the market growth.

Also, the increasing emphasis on Research and Development activity by key players will create lucrative opportunities for Myelofibrosis (MF) Treatment market growth.

Myelofibrosis is characterized by the presence of proteins called Janus-associated kinases (JAKs). There will also be an overview of emerging JAK inhibitor therapy as well as non-JAK inhibitor therapy which will also be focused, on the new challenge of switching from one JAK inhibitor therapy to another. Future therapies within this field are highly anticipated and new JAK inhibitor and non-JAK inhibitor therapies will also be discussed.

The treatment goals are typical to reduce splenomegaly and disease-associated symptoms, decrease complications such as thrombosis and hemorrhaging, and ideally slow disease progression. As the number of available agents for myelofibrosis management has increased in the past decade, therapeutic strategies mainly focus on symptom management.

Data Points	Key Statistics
Estimated Base Year Value (2022)	USD 712 Million
Expected Market Value (2023)	USD 749.05 Million
Anticipated Forecast Value (2033)	USD 1,280 Million
Projected Growth Rate (2023 to 2033)	5.5% CAGR

2018 to 2022 Myelofibrosis Demand Analysis vs. Forecast 2023 to 2033

The global demand for myelofibrosis is projected to increase at a CAGR of 5.5% during the forecast period between 2023 and 2033, reaching a total of USD 1,280 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%.

The growth in awareness regarding Myelofibrosis (MF) Treatment and the rise in the number of patients are also predicted to result in a rise in the number of products specifically related to the disease being produced during the forecast period of 2023 to 2032. In view of the complicated reimbursement associated with multiple patent expirations, the market for Myelofibrosis (MF) Treatment is projected to grow at a moderate pace throughout the forecast period. Myelofibrosis researchers worldwide are exploring strategies for treating and managing the side effects of treatment.

Ruxolitinib, an oral JAK1/JAK2 inhibitor and the only approved therapy for MF, is a potent oral JAK1/JAK2 inhibitor with clinical data, and agents in development are being studied. Patients with myelofibrosis can choose from a variety of treatment options based on their symptoms and circumstances. Furthermore, the onset of several diseases has led to the introduction of several drugs intended to reduce blood volume and relieve symptoms of various diseases.

Factors Driving the Global Myelofibrosis Treatments Market

Developing New Therapies Received a Major Boost During the Pandemic Crisis

Due to the increasing prevalence of various genetic disorders and the improvement in lifestyle choices, the myelofibrosis treatment market is expected to grow. Myelofibrosis treatment market revenue growth is expected to be driven by an increase in the number of smokers in the world, which will support revenue growth. Additionally, government investments are expected to increase in the healthcare infrastructure, especially in developing countries, which is expected to boost revenue growth.

Globally, increasing geriatric populations and new diagnostic tools are contributing to the increase in treatment options for myelofibrosis, which most commonly occurs to people over 50. The increase in anemic conditions and splenomegaly is further expected to result in a further increase in market conditions in the future. In addition to exposure to industrial chemicals and radiation, myelofibrosis is also associated with thrombocythemia and polycythemia vera. Therefore, these risk factors are becoming more prevalent among significant parts of the population, which drives market development.

Pipeline Drugs Seeking FDA Approval will Drive Market Growth

Idiopathic myelofibrosis is becoming more prevalent in developing economies, resulting in the need for different treatment options. Investing heavily in Research and Development, implementing favorable reimbursement policies, and having a large pool of myelofibrosis patients are factors that are causing the market to grow. As a result of the lack of treatment options, there is an urgent need for medical treatment for this disease.

With medical advancements focusing on patients suffering from myelofibrosis, the market is expected to gain significant traction. For instance, Gilead Sciences developed the drug CYT387, or momelotinib, to treat primary myelofibrosis, and Incyte Corporation developed an alternative dosing strategy for the current drug ruxolitinib.

In another instance, is a drug called pacritinib (Vonjo) has been approved by the Food and Drug Administration (FDA) for patients suffering from Myelofibrosis (MF) Treatment, a rare blood cancer that damages normal red blood cells. Due to its suitability for patients with severely low platelet counts, pacritinib should fill an important treatment gap since it is not as toxic as the other two drugs approved to treat AD, ruxolitinib (Jakafi) and fedratinib (Inrebic).

What are the Barriers to Myelofibrosis Treatment in the Market?

Delay in Diagnosis of Myelofibrosis Symptoms Impedes the Growth of the Patient?

Genetic mutations in stem cells in the bone marrow cause myelofibrosis. A majority of people with the disorder are over the age of 50 and don't show any symptoms early on. This will hamper the growth of the market.

Currently, the global myelofibrosis market is not experiencing revenue growth due to the lack of awareness regarding myelofibrosis disease and the high costs associated with treatment. Furthermore, in the near future, the side effects associated with myelofibrosis treatment drugs are expected to dampen market growth.

Country-Wise Insights

Why is North America the Biggest Market for Myelofibrosis Treatment?

Reimbursement Policies will increase Treatment Adoption for Myelofibrosis

Having a well-established healthcare system and a high awareness of cancer patients, North America is expected to hold 53% of the global healthcare market in 2023. This region is experiencing significant growth due to one of the fastest-growing diseases in the world, increased awareness about its manifestations, and reasonable reimbursement conditions in comparison with other economies.

Myelofibrosis prevalence in the United States was 19,815 cases in 2021, with the rate expected to climb during the study period, which is from 2019 to 2032. Increasing funding for research and healthcare infrastructure in the region is expected to contribute to North America dominating the global market for myelofibrosis. As a result of higher healthcare spending, favorable reimbursement conditions, and favorable reimbursement rates, the region has prospered.

What is the Scope of Myelofibrosis Treatment in Europe?

Growing Cancer Treatment Facilities are resulting in a Rise in Myelofibrosis Treatment

The European region is expected to dominate the global market for myelofibrosis treatments with a market share of 42% during the forecast period. With more government approvals for treatment and devices on the market, the demand for myelofibrosis treatment is expected to expand. For instance, the European Medicines Agency has approved momelotinib's marketing authorization application for myelofibrosis. Momelotinib, a novel treatment for myelofibrosis, has been approved by the European Medicines Agency (EMA) on the basis of data from the phase 3 MOMENTUM trial (NCT04173494).

As a result of ongoing research and the availability of advanced treatments, it is anticipated that the market will continue to grow. For instance, Imago BioSciences, Inc., as part of its ongoing Phase 2 clinical study evaluating bomedemstat in patients with advanced Myelofibrosis (MF) Treatment, a biopharmaceutical company that discovers and develops new medicines against blood cancers and other bone marrow disorders revealed positive results.

Furthermore, the National Institute of Health (NIH) lists myelofibrosis as a rare disease since there are about 0.5 cases per 100,000 people in the UK. As disposable incomes and spending capacities increase, the market is expected to grow further.

Category-wise Insights

How is Chemotherapy Treatments Impacting the Growth of the Myelofibrosis Market?

An increasing Number of Cancer Patients Will Increase Growth at a Significant Rate

Based on the treatment type of myelofibrosis treatment the market for chemotherapy is expected to grow the market. Chemotherapy drug market growth is expected to be boosted by rising cancer prevalence. Growth in healthcare expenditure also contributes to the growth of the chemotherapy market. Governments are also endeavoring to improve the healthcare infrastructure by increasing government funds available to the industry, and this will further impact the dynamics of the market.

A growing market for chemotherapy products will also be driven by the expansion of emerging markets and the introduction of novel products in the future. The recent approval of chemotherapeutics will play a significant role in the growth of the chemotherapy treatment market over the forecast period. The increasing prevalence of chemotherapy-induced myelofibrosis and the improvement in access to treatment have made chemotherapy-induced myelofibrosis a great opportunity for developing countries to generate revenue from the disease. As a result of all these factors, the market for myelofibrosis chemotherapy treatment and drug development is expected to grow.

How Do Oral Medications Have the Potential to Boost the Market for Myelofibrosis?

Demand for myelofibrosis treatment in Hospitals and Wound Care Centers to Gain Traction

Based on the route of administration, the global market is segmented into oral, parenteral, and others. The oral route of administration is expected to grow at a revenue share of 38% during the forecast period. Drug routes for treating cancer have propelled great awareness and adaption in the market. FDA recently approved the first drug specifically for patients with severely low platelet counts (thrombocytopenia) in the management of myelofibrosis with intermediate or high risk (thrombocytopenia).

Several technologies have improved the development of drugs for myelofibrosis on the market, as well as FDA-approved drugs on the market. For instance, AbbVie Inc. released new data from its Phase 2 trial of navitoclax with ruxolitinib. A presentation of the findings was made at the annual meeting of the American Association for Cancer Research 2022 (AACR 2022, abstract #LB108). First-of-its-kind, Navitoclax inhibits BCL-XL/BCL-2 in cancer cells via oral apoptosis (programmed cell death).

The Start-Up Ecosystem: What are Start-Ups Doing to Secure Future Growth Opportunities?

Some of the start-ups in the myelofibrosis treatment market?

• Myeloid Therapeutics: Therapeutics solutions are developed by Myeloid to treat cancer and other diseases. Myeloid cells containing CARs are activated by the company's ATAK platform, which triggers tumor-specific phagocytosis and secretions of proinflammatory cytokines, which help kill tumor cells. After successfully completing in vitro and animal studies, the technology is in the preclinical stage.
• Sierra Oncology: Develops targeted therapies for cancer treatment. In addition to Momelotinib, myelofibrosis is treated with ACVR1 inhibitors, JAK1 & JAK2 inhibitors. Solid tumors and heme malignancies are also candidates for SRA515.
• Orsenix is a US-based start-up. A biotechnology company developing cancer therapeutics. In addition to ORH-2014, the company offers treatment for acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) is a capsule form that can be taken orally. Besides treating myeloid cancers, ATO is also being developed in order to treat myeloid disorders, such as myelodysplastic syndromes, myelofibrosis, and glioblastoma.

Market Competition

Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.

• An investigational selective oral PIM1 kinase inhibitor, TP-354, presented new data from Sumitomo Pharma Oncology, Inc., a company specializing in novel cancer therapeutics. In patients previously treated with or ineligible for JAK inhibitor therapy or ineligible for JAK inhibitor therapy, TP-3654 is an investigational selective oral PIM1 kinase inhibitor. A presentation of these results will be made at the 2022 American Society of Hematology's Annual Meeting & Exposition in New Orleans, LA, from December 10-13, 2022.
• Myeloproliferative neoplasms (MPNs) and other bone marrow diseases are treated by Imago BioSciences, Inc., a clinical-stage biopharmaceutical company, announced that the first experimental drug (methotrexate) and ruxolitinib (Jakafi®) has been administered to a patient with MF.). In the United States, ruxolitinib is approved by the Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 749.05 Million
Market Value in 2033	USD 1,280 Million
Growth Rate	CAGR 5.5%
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment Type, Route of Administration, End-User, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC,= South Africa, Israel
Key Companies Profiled	Pfizer Inc.; F. Hoffmann-La Roche Ltd; Mylan N.V.; Fresenius Kabi AG; Hikma Pharmaceuticals PLC; Novartis AG; Teva Pharmaceutical Industries Ltd.; Bristol Myers Squibb Company; GSK Plc.; Bayer AG; Sun Pharmaceutical Industries Ltd; Boehringer Ingelheim International Gmbh; Sanofi
Customization	Available Upon Request

Key Segments Profiled in the Myelofibrosis Market Industry Survey?

By Treatment Type:

• Targeted Therapy
• Chemotherapy
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By End User:

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Frequently Asked Questions

What is the projected growth of the market for myelofibrosis until 2033?

FMI projects the global myelofibrosis market to expand at a 5.5% value CAGR by 2033.

What is the estimated market value of the myelofibrosis market expected in 2023?

The global myelofibrosis market is estimated at a market value of USD 749.05 Million.

What is the estimated market value of the myelofibrosis market expected in 2033?

The global myelofibrosis market is expected to garner a market value of USD 1,280 Million.

Which region is forecast to be the most lucrative for myelofibrosis market growth?

North America is expected to hold 53% of the myelofibrosis market.

Which are some prominent myelofibrosis manufacturers in the market?

Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., and Fresenius Kabi AG are some prominent myelofibrosis manufacturers in the market.

Which route of administration myelofibrosis is expected to account for the largest share in the forecast period 2023-2033?

The oral route of the administration market will hold 33% of the market value in 2023.